JUBILANT
SpecialtyJUBILANT is a specialty pharmaceutical company focused on Oncology, Respiratory, Infectious Disease. Key products include DRAX EXAMETAZIME.
JUBILANT's Key Drugs
JUBILANT's core commercial portfolio centers on DRAX EXAMETAZIME, RUBY-FILL, spanning Oncology and Respiratory — its most strategically important drugs approved in the last 15 years.
JUBILANT's Recent FDA Approvals
New NDA/BLA approvals for JUBILANT over the last two years — novel drugs only, excluding generics and label supplements.
JUBILANT's Therapeutic Areas
JUBILANT's approved drugs and pipeline span 4 therapeutic areas, led by Oncology and Respiratory, across 0 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
JUBILANT's Top Competitors
JUBILANT's closest competitors by therapeutic-area and drug-target overlap include Merck, GSK, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
JUBILANT Pipeline Snapshot
JUBILANT has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DRAX EXAMETAZIME leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (0)
Company Info
- First Approval
- 1978-11-28
- Latest
- 2025-05-22
- Applications
- 6